AIGH Capital Management LLC Buys 148,199 Shares of PolyPid Ltd. (NASDAQ:PYPD)

AIGH Capital Management LLC lifted its stake in shares of PolyPid Ltd. (NASDAQ:PYPD) by 21.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 827,867 shares of the company’s stock after acquiring an additional 148,199 shares during the period. PolyPid makes up 0.8% of AIGH Capital Management LLC’s investment portfolio, making the stock its 23rd biggest position. AIGH Capital Management LLC owned about 8.12% of PolyPid worth $2,509,000 as of its most recent filing with the SEC.

Separately, Rosalind Advisors Inc. lifted its stake in PolyPid by 50.6% during the fourth quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock worth $3,108,000 after purchasing an additional 343,353 shares during the last quarter. Hedge funds and other institutional investors own 26.47% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PYPD. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th. HC Wainwright decreased their price target on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, December 26th. Finally, Rodman & Renshaw initiated coverage on shares of PolyPid in a research note on Tuesday, January 28th. They issued a “buy” rating and a $13.00 price objective for the company.

PolyPid Trading Up 0.7 %

Shares of PYPD stock opened at $2.74 on Friday. The business has a 50-day moving average of $2.97 and a 200 day moving average of $3.18. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. PolyPid Ltd. has a 1-year low of $2.37 and a 1-year high of $5.09. The stock has a market capitalization of $27.92 million, a PE ratio of -0.55 and a beta of 1.27.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). As a group, sell-side analysts anticipate that PolyPid Ltd. will post -1.79 earnings per share for the current year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.